LEADER 03748nam  22005295  450 
001 9910298412803321
005 20200629225220.0
010   $a3-319-95133-5
024 7 $a10.1007/978-3-319-95133-1
035   $a(CKB)4100000006674719
035   $a(MiAaPQ)EBC5528908
035   $a(DE-He213)978-3-319-95133-1
035   $a(PPN)230539394
035   $a(EXLCZ)994100000006674719
100   $a20180927d2018      u|         0
101 0 $aeng
135   $aurcnu||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aDelta Opioid Receptor Pharmacology and Therapeutic Applications /$fedited by Emily M. Jutkiewicz
205   $a1st ed. 2018.
210  1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2018.
215   $a1 online resource (338 pages)
225 1 $aHandbook of Experimental Pharmacology,$x0171-2004 ;$v247
311   $a3-319-95131-9 
327   $aPart 1. DOPR Ligands -- 1. Delta Opioid Receptor (DOR) Ligands and Pharmacology: Development of Indolo- and Quinolinomorphinan Derivatives Based on the Message-Address Concept -- 2. Multifunctional Opioid Ligands -- 3. Contribution of Delta-Opioid Receptors to Pathophysiological Events Explored by Endogenous Enkephalins -- Part 2. DOPR Signaling -- 4. Ligand-Directed Signaling at the Delta Opioid Receptor -- 5. Delta Opioid Receptor Expression and Function in Primary Afferent Somatosensory Neurons -- 6. Evidence and Function Relevance of Native DOR?MOR Heteromers -- Part 3. DOPR and Disease -- 8. The Delta Opioid Receptor in Pain Control -- 9. Delta Opioid Receptors and Modulation of Mood and Emotion -- 10. Delta Opioid Pharmacology in Relation to Alcohol Behaviors -- 11. Delta Opioid Receptors: Learning and Motivation -- 12. Delta Opioid Pharmacology in Parkinson?s Disease -- 13. Delta Opioid Receptor and Peptide: A Dynamic Therapy for Stroke and Other Neurological Disorders -- 14. Delta Opioid Receptors and Cardioprotection -- 15. The Roles of Opioid Receptors in Cutaneous Wound Healing. .
330   $aThis volume describes our current understanding of the biological role of the delta-opioid receptor (DOR) system, focusing on its unique mechanisms of receptor trafficking and signaling in disease states. Part 1 covers the endogenous ligands that regulate the DOR system as well as novel compounds and therapies used to modulate the DOR system. Part 2 describes new insights into the localization and trafficking of the DOR and how ligand-directed signaling alters the fate of the receptor. Part 3 concentrates on the potential role of the DOR system in disease states, such as pain, mood, addiction, and Parkinson?s disease. Throughout the book, the DOR system as a target for drug development will be discussed.
410  0$aHandbook of Experimental Pharmacology,$x0171-2004 ;$v247
606   $aPharmacology
606   $aNeurosciences
606   $aHuman physiology
606   $aPharmacology/Toxicology$3https://scigraph.springernature.com/ontologies/product-market-codes/B21007
606   $aNeurosciences$3https://scigraph.springernature.com/ontologies/product-market-codes/B18006
606   $aHuman Physiology$3https://scigraph.springernature.com/ontologies/product-market-codes/B13004
615  0$aPharmacology.
615  0$aNeurosciences.
615  0$aHuman physiology.
615 14$aPharmacology/Toxicology.
615 24$aNeurosciences.
615 24$aHuman Physiology.
676   $a615.7822
702   $aJutkiewicz$b Emily M$4edt$4http://id.loc.gov/vocabulary/relators/edt
906   $aBOOK
912   $a9910298412803321
996   $aDelta opioid receptor pharmacology and therapeutic applications$91772463
997   $aUNINA